Edwards Lifesciences Corporation

(New York Stock Exchange)
Back to all articles
Bullish +65

Azimuth Capital Investment Management LLC Decreases Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat

AI-generated analysis

📈 Edwards Lifesciences reported quarterly EPS of $0.78, beating analyst estimates of $0.74.

💰 Revenue grew 13.6% year over year to $1.74 billion, surpassing the $1.70 billion consensus.

🔮 The company issued Q3 2026 EPS guidance of $0.71–$0.77 and full-year 2026 guidance of $2.95–$3.05.

📉 Azimuth Capital reduced its stake by 9.9% in the second quarter, selling 22,092 shares.

🏦 Institutional investors collectively own 79.46% of Edwards Lifesciences Corporation.

📊 The stock trades at a PE ratio of 51.72 with a market capitalization of $51.82 billion.

🎯 Analysts maintain a 'Moderate Buy' consensus with an average price target of $100.27 versus the current price of ~$90.

📈 UBS Group initiated coverage with a 'Buy' rating and a $110.00 price target.

🔼 JPMorgan Chase raised its price target from $100.00 to $105.00 with an 'overweight' rating.

📉 VP Daniel J. Lippis sold 619 shares under a Rule 10b5-1 trading plan on August 11th.

📉 SVP Andrew M. Dahl sold 544 shares on August 31st, reducing his ownership by 3.53%.

🏥 The company focuses on prosthetic heart valves and transcatheter aortic valve replacement (TAVR) technologies.

Bullish Signals
  • Edwards Lifesciences beat quarterly EPS estimates of $0.74 with a reported result of $0.78.
  • Revenue increased 13.6% year over year to $1.74 billion, exceeding analyst expectations of $1.70 billion.
  • The company issued optimistic forward guidance for Q3 2026 EPS ($0.71–$0.77) and full-year 2026 EPS ($2.95–$3.05).
  • Institutional ownership remains high at 79.46%, indicating strong confidence from major investors.
  • Analyst consensus is 'Moderate Buy' with an average price target of $100.27, implying significant upside from the current ~$90 price.
  • UBS Group initiated coverage with a 'Buy' rating and a high $110.00 price target.
  • JPMorgan Chase upgraded its stance to 'overweight' and raised its price target to $105.00.
  • Royal Bank of Canada increased its price objective to $110.00 with an 'outperform' rating.
  • Leerink Partners upgraded the stock from 'market perform' to 'outperform' and raised the price target to $101.00.
Risk Factors
  • Azimuth Capital Investment Management LLC decreased its holdings by 9.9% in the second quarter, selling 22,092 shares.
  • Insider sales occurred recently, with VP Daniel J. Lippis and SVP Andrew M. Dahl reducing their positions under pre-arranged trading plans.
Full Analysis
Edwards Lifesciences Corporation (NYSE: EW) reported strong quarterly financial results, posting earnings per share (EPS) of $0.78, which beat the analyst consensus of $0.74. Revenue increased by 13.6% year over year to reach $1.74 billion, exceeding expectations of $1.70 billion. The company maintains a robust balance sheet with a current ratio of 4.52 and a debt-to-equity ratio of 0.06, reflecting its strong financial position in the structural heart disease market. The company has issued forward guidance for the third quarter of 2026, projecting EPS between $0.71 and $0.77, and full-year 2026 EPS between $2.95 and $3.05. Analyst sentiment remains favorable with a consensus rating of 'Moderate Buy' and an average price target of $100.27, significantly above the reported share price of approximately $90. Several major analysts have recently raised their price targets or upgraded ratings, citing continued growth potential. Institutional ownership stands at 79.46%, though Azimuth Capital Investment Management LLC reduced its stake by 9.9% in the second quarter, selling 22,092 shares while retaining a position valued at roughly $18.2 million. Despite this reduction, other hedge funds have initiated new positions or increased holdings during various quarters, indicating continued institutional interest. Insider trading activity shows minor sales by executives under pre-arranged plans, with corporate insiders owning 0.31% of the stock.